case_images: PMC4749787_01
case_images: Pet CT showing accumulation of 18-FDG in the right parotid gland.
case_images: CRIONM2016-3965283.001.jpg
case_images: PMC4749787_01_CRIONM2016-3965283.001.jpg
case_images: fig1
case_images: Staging FDG-PET CT scan was obtained showing accumulation of 18-FDG in the right parotid and ruled out other distant or locoregional metastases (Figure 1).
case_images: Parotid: H&E x40: neoplastic ducts (right upper part of the image) invading the parotid parenchyma (left lower part of the image).
case_images: CRIONM2016-3965283.002.jpg
case_images: PMC4749787_01_CRIONM2016-3965283.002.jpg
case_images: fig2
case_images: The anatomic pathology report confirmed the secondary nature of the tumor (of breast origin) invading the parotid parenchyma with perineural and perivascular invasion (Figure 2).
case_images: Parotid: immunostain with anti-estrogen receptors antibody x40: the nuclei of the malignant cell are highlighted in brown. Parotid ducts are seen in the lower part of the image.
case_images: CRIONM2016-3965283.003.jpg
case_images: PMC4749787_01_CRIONM2016-3965283.003.jpg
case_images: fig3
case_images: Although immunocytochemistry was not done on the FNA sample and was not needed for diagnosis, immunostaining with anti-estrogen receptor (ER) antibodies was performed on the final surgical pathology specimen and further supported the diagnosis as the tumoral cells were ER positive (Figure 3).
case_images: GATA3 nuclear expression in neoplastic cells (GATA3 immunostaining x200) confirming the breast origin of the parotid tumor.
case_images: CRIONM2016-3965283.004.jpg
case_images: PMC4749787_01_CRIONM2016-3965283.004.jpg
case_images: fig4
case_images: GATA3 immunostaining, a specific marker for breast cancer, was also done confirming the breast origin of the tumor (Figure 4).